DEKA Biosciences

Deka BioSciences Inc. is incorporated and initiated operations in January 2019. Deka is focused on generating optimized disease specific IL-10 variants, coupled with novel T_1/2 life extension technology (Diakines^TM), to treat patients in the fields of Oncology, IBD/Crohn’s and Fatty Liver Disease. We believe the timing is right, given the challenges multiple targets/programs have experienced over the last few years to deliver value for all stakeholders and most importantly, benefit to the patients.